MedTrace Logo

The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder

NCT03715465 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-11-25

Study results available
· View outcomes & findings →

Summary

This study will test whether measuring the circadian clock during treatment of delayed sleep-wake phase disorder results in greater improvements in sleep compared to estimating the circadian clock.

Conditions

  • Delayed Sleep Phase Syndrome

Interventions

DRUG

Melatonin 0.5 MG

Melatonin tablet

OTHER

Dim Light Melatonin Onset (salivary)

Test to determine the time of melatonin onset in saliva under dim light conditions

Sponsors & Collaborators

Principal Investigators

  • Leslie Swanson, Ph.D. · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2021-11-05
Completion
2021-11-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03715465 on ClinicalTrials.gov